Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

LCTX Lineage Cell Therapeutics Inc

Price (delayed)

$0.6643

Market cap

$151.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$106.06M

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house ...

Highlights
Lineage Cell Therapeutics's quick ratio has increased by 42% YoY and by 6% QoQ
LCTX's EPS is up by 38% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of LCTX
Market
Shares outstanding
228.36M
Market cap
$151.7M
Enterprise value
$106.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
15.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.1
Earnings
Revenue
$9.56M
Gross profit
$9.29M
Operating income
-$21.32M
Net income
-$16.21M
EBIT
-$16.21M
EBITDA
-$15.61M
Free cash flow
-$22.82M
Per share
EPS
-$0.08
EPS diluted
-$0.08
Free cash flow per share
-$0.1
Book value per share
$0.35
Revenue per share
$0.04
TBVPS
$0.24
Balance sheet
Total assets
$111.75M
Total liabilities
$34.1M
Debt
$2.24M
Equity
$79.03M
Working capital
$36.9M
Liquidity
Debt to equity
0.03
Current ratio
3.82
Quick ratio
3.68
Net debt/EBITDA
2.92
Margins
EBITDA margin
-163.3%
Gross margin
97.2%
Net margin
-169.6%
Operating margin
-223.1%
Efficiency
Return on assets
-15.3%
Return on equity
-22.2%
Return on invested capital
N/A
Return on capital employed
-16.4%
Return on sales
-169.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
-2.72%
1 week
29.97%
1 month
44.41%
1 year
-32.21%
YTD
32.2%
QTD
47.1%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$9.56M
Gross profit
$9.29M
Operating income
-$21.32M
Net income
-$16.21M
Gross margin
97.2%
Net margin
-169.6%

LCTX financials

The net margin has grown by 43% YoY and by 13% from the previous quarter
The company's net income rose by 31% YoY and by 13% QoQ
LCTX's operating margin is up by 28% year-on-year
The gross profit has grown by 26% YoY

Price vs fundamentals

How does LCTX's price correlate with its fundamentals

LCTX Price vs fundamentals

LCTX Earnings waterfall

LCTX Price vs fair value

Growth

What is Lineage Cell Therapeutics's growth rate over time

LCTX growth chart

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
15.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.1

Valuation vs average

Price to earnings (P/E)

LCTX's EPS is up by 38% year-on-year and by 11% since the previous quarter

Price to book (P/B)

LCTX's P/B is 30% below its 5-year quarterly average of 2.8
LCTX's equity is up by 9% YoY

Price to sales (P/S)

LCTX's price to sales (P/S) is 73% less than its 5-year quarterly average of 60.0 and 9% less than its last 4 quarters average of 17.8
The revenue has grown by 19% YoY

Efficiency

How efficient is Lineage Cell Therapeutics business performance
LCTX's ROS is up by 43% year-on-year and by 13% since the previous quarter
LCTX's return on equity is up by 35% year-on-year and by 15% since the previous quarter
Lineage Cell Therapeutics's ROA has increased by 31% YoY and by 14% from the previous quarter

Dividends

What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LCTX.

Financial health

How did Lineage Cell Therapeutics financials performed over time

Assets vs liabilities

Lineage Cell Therapeutics's quick ratio has increased by 42% YoY and by 6% QoQ
The current ratio has grown by 41% year-on-year and by 4.7% since the previous quarter

Debt vs equity

The debt is 97% less than the equity
The debt has contracted by 31% YoY and by 11% from the previous quarter
The debt to equity has contracted by 25% YoY

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.